Clinical Trial Update: Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, reactogenicity, and immunogenicity of GSK's maternal unadjuvanted RSV vaccine in healthy pregnant women and their infants; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV maternal unadjuvanted vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED | Results posted: 2021-12-13